Abstract: This invention provides a method for treatment of hepatic cancer with the use of an anti-tumor agent in combination with the REIC/Dkk-3 gene. This invention also provides a therapeutic agent for treatment of hepatic cancer used in combination with an anti-tumor agent, which comprises, as an active ingredient, the REIC/Dkk-3 gene.

Abstract: A film formation method is provided with a step for disposing a non-electroconductive long thin tube 102 in a chamber 101 in which the internal pressure thereof is adjustable, generating a plasma inside the long thin tube 102 in a state in which a starting material gas including a hydrocarbon is supplied, and forming a diamond-like carbon film on an inner wall surface of the long thin tube 102. The long thin tube 102 is disposed in the chamber 101 in a state in which a discharge electrode 125 is disposed in one end part of the long thin tube 102 and the other end part is open. An alternating-current bias is intermittently applied between the discharge electrode 125 and a counter electrode 126 provided so as to be separated from the long thin tube 102.

Abstract: The present invention relates to a method including culturing a C1 compound-assimilating bacterium, which is a methylotroph, and/or a yeast by using a medium comprising, for example, a C1 compound and/or glycerol as a carbon source, to thereby produce EGT.

Abstract: According to an aspect of the present invention, there is provided a positive electrode material which contains a positive electrode active material, and a dielectric material having a perovskite crystal structure. In the positive electrode material, in an X-ray diffraction pattern (vertical axis: diffraction intensity, horizontal axis: diffraction angle 2? (rad)) obtained by X-ray diffraction measurement using a CuK? ray, a highest intensity peak which is a peak derived from the dielectric material and has the highest intensity is in a range satisfying 2?=31° to 32°, and a half width x of the highest intensity peak satisfies the following expression: 0.22?x?0.33.

Abstract: The present invention addresses the problem of providing, by a method in which an expensive manufacturing apparatus is not required, an implant material having osteoconductivity superior to that of an implant material containing an aromatic polyether ketone. The present invention pertains to: said method including immersing an aromatic polyether ketone in a strong base solution in the absence of a calcium ion, and immersing an aromatic polyether ketone, which is obtained by the immersing, in a liquid containing a phosphorus-containing compound; and an implant material obtained by said method.

Abstract: The method for producing wet spun fibers/a wet formed film using a double-walled pipe type micronozzle apparatus according to the present invention is a production method, wherein, in a step of extruding an internal phase comprising a fiber/film material and a good solvent for the fiber/film material in a linear form from the circular/rectangular end of the internal pipe of the apparatus into an external phase comprising a poor solvent for the fiber/film material, the external phase flowing in the external pipe of the apparatus, the ratio of the external phase flow rate to the internal phase flow rate is set to 1 or more, and further for the wet spun fibers, the external phase line speed at the orifice portion at which the internal phase and the external phase merge is set to 0.1 ms?1 or more.

Abstract: Provided is a magnetic field measuring device which has good temperature stability and which enables an improvement by making it possible for the sensitivity of a Hall element, a magnetic impedance (MI) element or a magnetic resistance (MR) element, which are conventionally used extensively, to be set freely. This magnetic field measuring device comprises: a temperature maintaining means for maintaining an extremely low temperature state in which a superconductor adopts a superconducting state; a magnetic sensor which is provided inside the temperature maintaining means to detect a magnetic field; and a magnetic field space forming means for forming a magnetic field space specific to the superconducting state, by adopting a superconducting state inside the temperature maintaining means; wherein the magnetic sensor is disposed in the magnetic field space.

Abstract: An embodiment relates to a method of evaluating a lymphatic system function including: selecting one or a plurality of lymphatic routes to be evaluated from a plurality of lymphatic routes existing in four limbs; determining an injection site of a visualization agent based on information on the selected lymphatic route and injection sites of peripheries of the four limbs corresponding to the selected lymphatic route; injecting the visualization agent from the selected injection site; and visualizing the injected visualization agent and evaluating functions of the one or plurality of lymphatic routes to be evaluated.

Abstract: An ultrasonic diagnostic device according to an embodiment includes processing circuitry. The processing circuitry estimates a health state on the basis of a measurement value measured using ultrasonic image data. The processing circuitry determines an additional examination used to diagnose the health state, on the basis of the estimated health state. The processing circuitry outputs information indicative of the health state and the additional examination.

Abstract: In one embodiment, the present invention provides an anti-cancer-associated non-tumor cell agent. In one embodiment, the present invention relates to an anti-cancer-associated non-tumor cell agent comprising an oncolytic virus comprising a p53 gene. In one embodiment, the present invention relates to an anti-cancer-associated non-tumor cell preparation comprising a recombinant virus comprising: a first gene cassette containing a telomerase reverse transcriptase promoter, an E1A gene, an IRES sequence and an E1B gene; and a second gene cassette containing a promoter and a p53 gene.

Abstract: The present disclosure relates to a positive electrode material for a lithium secondary battery which includes a positive electrode active material and a dielectric. The dielectric is a composite oxide represented by a general formula AmBnO? and has a dielectric constant of 10 to 500. Here, m and n are real numbers that satisfy 1.01?m/n?1.6, ? is a value that is determined so that charge neutral conditions are satisfied, A is one or more elements among alkali metal elements, alkaline earth metal elements, rare earth elements, Cu, Pb and Bi, and B is one or more elements among transition metal elements and Sn.

Abstract: Provided is a medicament useful for cardiovascular diseases. An agent for prevention and/or treatment of a cardiovascular diseases, comprising a combination of pemafibrate or a salt thereof and an HMG-CoA reductase inhibitor.

Abstract: There is provided a drug for preventing or treating inflammatory bowel disease, comprising as an active ingredient an RXR agonist which is a compound represented by Formula (1). In Formula (1), it is preferred that: R1 is an alkyl group; R2 is an alkyl group; W is NR3, and R3 is an alkyl group; X1 is CH; Y1 is N; X2 and Y2 are CH; and Z is a carboxyl group. Thus, a drug capable of strongly preventing or treating inflammatory bowel disease while suppressing the onset of side effects is provided.

Abstract: The invention may provide a puncture robot that can precisely move a needle in the puncture direction by setting needle position in a CT gantry. Provided is a puncture robot comprising a puncture unit, puncture robot being configured such that: the puncture unit comprises a puncture needle, an arm unit, a frame unit, and a base unit; the frame unit comprises a first frame and a second frame that are each provided with an advancing and retracting shaft, and a connecting rod; the arm unit comprises an upper arm and a lower arm, with the puncture needle being mounted to be parallel to the advancing and retracting shaft and the upper arm and the lower arm are advanced and retracted along the advancing and retracting shaft.

Abstract: The present invention relates to an immune function inspection method, comprising obtaining peripheral blood from a human test subject; applying an immunostimulant; inspecting changes in intracellular calcium ion concentration in peripheral blood mononuclear cells (PBMC) or CD8T cells; determining a decrease in systemic immune function when the intracellular calcium ion concentration in PBMC or CD8T cells transiently increases after the application of the immunostimulant and then returns to the state before the stimulation; and determining normality of systemic immune function when the intracellular calcium ion concentration in PBMC or CD8T cells is in an upward trend after the application of the immunostimulant.

Abstract: A method for treating an inflammatory respiratory disease, comprising administering an effective amount of an RXR agonist represented by formula (1) or (2) as an active ingredient. wherein D, R1, R2, X, Y, Z, R3, R4, X1, Y1, X2, Y2 and Z1 are defined.

Abstract: The present invention relates to a method including culturing a C1 compound-assimilating bacterium, which is a methylotroph, and/or a yeast by using a medium comprising, for example, a C1 compound and/or glycerol as a carbon source, to thereby produce EGT.

Abstract: A method is provided that allows the sulfur component concentration in gasoline to be estimated to high precision. The measuring method of the disclosure is a method of measuring the concentration of sulfur components in gasoline that contains sulfur components and aromatic components. The measuring method of the disclosure comprises: (A1) removing a portion of the gasoline by gasification to lower the proportion of the aromatic component concentration with respect to the sulfur component concentration in the gasoline, (A2) measuring values related to the refractive index of the gasoline, and (A3) measuring the sulfur component concentration in the gasoline based on the values related to the refractive index.

Abstract: It is an object of the present invention to provide a novel therapeutic agent for hepatoma viruses. Specifically, the present invention relates to an anti-hepatoma virus agent, containing as an active ingredient a compound represented by the following Formula (I) or a pharmaceutically acceptable salt thereof: (wherein R1 is fluorine or hydrogen).

Abstract: The present invention provides: a complex of a mercaptoundecahydrodecaborate (BSH) and a peptide, the complex for boron neutron capture therapy (BNCT); a method for producing the complex; and a cancer therapy using the complex.